Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. reports corporate news around its Bitcoin treasury strategy and its medical-device and software business. Company updates have described Bitcoin as the primary treasury reserve asset, with recurring disclosures on Bitcoin purchases, holdings, BTC Yield and related financing activity through equity, debt and operating cash flow.
Semler Scientific news also covers healthcare initiatives, including QuantoFlo device and software for early detection of peripheral artery disease and CardioVanta, a wholly owned subsidiary focused on early detection of heart failure and cardiac arrhythmia monitoring. Other recurring items include operating results, board and strategy roles, capital-structure updates and shareholder matters.
Semler Scientific (SMLR) reported strong financial results for the year ended December 31, 2020. Revenues rose to $38.6 million, reflecting an 18% increase from $32.8 million in 2019. Pre-tax net income surged 54% to $16.5 million with a 43% margin. However, net income fell 7% to $14.0 million due to a prior year's tax benefit. The company’s cash position improved significantly, reaching $22.1 million. Looking to 2021, Semler anticipates continued profitability amid challenges posed by COVID-19 regulations.
Semler Scientific, Inc. (SMLR) announced its participation in the H.C. Wainwright Global Life Sciences Conference. CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present a company overview on March 9, 2021, accessible on-demand at semlerscientific.com/hcwr-global. Additionally, management will engage in one-on-one investor calls on March 10. Semler specializes in technology solutions for improving clinical effectiveness, focusing on chronic disease evaluation.
Semler Scientific, Inc. (OTCQB: SMLR) announced it will release financial results for Q4 and the full year ended December 31, 2020, on March 1, 2021, after U.S. markets close. CEO Doug Murphy-Chutorian will host a conference call at 4:30 PM ET the same day, joined by senior finance officials. Participants are encouraged to pre-register for immediate access to the call. Semler Scientific focuses on technology solutions that enhance healthcare provider effectiveness and efficiency and has received FDA clearance for its flagship product QuantaFlo®, aiding in diagnosing peripheral arterial disease.
Semler Scientific, Inc. (SMLR), based in San Jose, California, announced participation in several upcoming virtual investor conferences in September 2020. The events include the 5th Annual Colliers Securities Conference on September 10, the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15, and the 4th Annual Best Ideas Growth (BIG4) Conference on September 17. The company focuses on improving healthcare efficiency with technology solutions, notably its QuantaFlo® product, which assists in diagnosing peripheral arterial disease.
Semler Scientific, Inc. (OTCQB: SMLR) announced the appointment of Daniel Messina to its Board of Directors effective August 13, 2020. With nearly 40 years of healthcare and technology experience, Messina brings valuable insights to the company. His prior roles include co-founder of HandsFree Health and leadership positions at West Corporation and Aetna Health. The Board now comprises four members, aiming to enhance strategic growth and the development of proprietary products for chronic disease evaluation.